根据疾病位置对皮下因弗利克西马布的内镜反应:对LIBERTY-CD研究的后期分析
Bruce E Sands1, Stefan Schreiber2, Marla C Dubinsky3
1Dr Henry D. Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York.
皮下注射的infliximab (IFX SC) 有效地治疗了克罗恩病.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 克罗恩氏病 (CD) 治疗疗效因位置不同而有所不同,而状腺疾病则具有挑战性.
- 皮下注射的infliximab (IFX SC) 是一种针对CD的向治疗方法.
研究的目的:
- 根据疾病位置,研究IFX SC在中度至严重活性CD中的疗效.
- 使用第三阶段LIBERTY-CD试验的数据进行分析.
主要方法:
- 包括第10周对静脉注射IFX诱导疗法的反应者.
- 随机选择的患者接受IFX SC (120毫克每隔一周) 或安慰剂进行维护.
- 根据大肠主导或大肠主导的CD分组患者,并评估到第54周的结果.
主要成果:
- 在54周,IFX SC显著改善了疗效终点与安慰剂相比,无论疾病的位置.
- 治疗效应在包括终端大肠在内的大肠段中是一致的.
- 较高的血清IFX水平与临床缓解和内镜反应相关.
结论:
- IFX SC维持疗法在克罗恩病中表现出一致的疗效,无论疾病的位置如何.
- 在所有细节中观察到有效的治疗,包括具有挑战性的终端大肠.
- 皮下注射的infliximab为各种CD呈现提供了一个可行的治疗选择.
更多相关视频
09:08Investigating Target Gene Function in a CD40 Agonistic Antibody-induced Colitis Model using CRISPR/Cas9-based Technologies
Published on: June 2, 2021
07:04Immunostimulatory Agent Evaluation: Lymphoid Tissue Extraction and Injection Route-Dependent Dendritic Cell Activation
Published on: September 16, 2018
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
